ADARx secures $200m to advance clinical programmes
10 Aug 2023
Phase 1Gene Therapy
Preview
Source: Pharmaceutical Technology
ADARx is focused on the development of next-generation RNA therapeutics. Credit: MattL_Images / Shutterstock.com.
Preview
Source: Pharmaceutical Technology
ADARx Pharmaceuticals has concluded an oversubscribed Series C financing, securing $200m for advancing its clinical programmes, including ADX-324 and ADX-038.
Led jointly by TCGX and Bain Capital Life Sciences, the financing round witnessed participation from new investors such as Commodore Capital, Cormorant Asset Management, Invus, Marshall Wace, Redmile Group, HBM Healthcare Investments and Blackrock.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - AVID-200 in Myelofibrosis GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - BBI-3000 in Breast Cancer GlobalData
View allCompanies IntelligenceHBM Healthcare Investments LtdLilly Asia venturesADARx Pharmaceuticals IncBain Capital Life SciencesMarshall Wace LLPView all
It also involved existing investors SR One Capital Management, OrbiMed, Lilly Asia Ventures and Ascenta Capital.
ADX-324 offers a new method to treat hereditary angioedema, a genetic disease characterised by painful, rapid and potentially life-threatening episodes of swelling.
The company is developing ADX-038 to treat multiple complement-mediated diseases.
It will also use the funding to support the development of a pipeline of mRNA silencing or editing candidates to treat several diseases.
ADARx Pharmaceuticals president and CEO Dr Zhen Li stated: “The early Phase I clinical data strongly support the potential of ADX-324 to be the best-in-class treatment for patients suffering from hereditary angioedema.
“Moreover, the clinical data validate our proprietary targeted delivery PLR platform and our broad SPE technology. With this financing, we are well-positioned to achieve our clinical milestones for multiple clinical programmes and to build a leading company in RNA therapeutics.”
The company has a pipeline of RNA therapeutics to treat diseases across a range of therapeutic areas.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.